In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs - STAT

As reported by STAT

AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a competitive billion-dollar market.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on STAT ↗

Market Samachar is a news aggregator. This article was originally published by STAT. Tap the button above to read the full story on their site.

INDIAN This AI stock surges over 600% YTD; delivers bigger returns than Nvidia, SanDisk, Micron and Intel mint - markets
GLOBAL Fundraiser launched to secure crafting shop future BBC News
CRYPTO Tokenized stock transfer volume jumps 415% in 30 days to $29.5B Cointelegraph.com News
CRYPTO Bernie Sanders Vows Legislation to 'Stop Flock and AI Mass Surveillance' Decrypt
CRYPTO Bitcoin's Oldest Coins Are Waking Up in 2026 at a Pace Rarely Seen Decrypt
INDIAN 165 Licences Suspended, 750 Notices Issued: Tukaram Mundhe Says Hotel Industry's Criticism Lacks Facts NDTV Profit - Latest
INDIAN Iran War Reshapes Global Energy: Why China, EVs, Renewables Are Emerging Winners And Where Does India Stand NDTV Profit - Latest
INDIAN iPhone Ultra Leak Claims Red, Black And White Colours; Gurman Disagrees NDTV Profit - Latest

In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs - STAT

More from Market Samachar